Assessment of GCC pharmaceutical market for a global European pharma major

  • Analysed potential for entry into the GCC pharmaceutical market

  • Helped client understand socio-economic and health policies in GCC countries


CLIENT CHALLENGES
  • A global European pharma major wanted to assess the market’s viability as an investment opportunity
  • Key challenges were :
    • Scarcity of data in GCC countries
    • Highly fragmented pharmaceutical markets in GCC countries
    • The need to understand socio-economic determinants and government policies
OUR APPROACH
  • Market assessment :
    • Estimated market size using the bottom-up approach
    • Assessed market dynamics, drivers and barrier to entry
    • Assessed the top players in market, their revenue streams and plans
    • Assessed sub-sectors based on competition
  • Socio-economic determinants :
    • Tracked spending as a percentage of GDP on the healthcare sector and per capita expenditure on healthcare
    • Gained an understanding of the proportion of the aged population and incidence of chronic disease
    • Analysed participation of private hospitals and health insurance
  • Government/health policies :
    • Tracked healthcare-related policies
    • Tracked regulatory, pricing and reimbursement policies
    • Gained an understanding of government policies in terms of setting up manufacturing bases and foreign investments
IMPACT DELIVERED
  • Advised on sub-sectors with unmet need and market attractiveness
  • Assessed possible market drivers and barriers to entry
Thank you for sharing your details

Your file will start downloading automatically

If it does not download within 1 minute,

Share this on

What we have done

Product launch strategy for European biopharmaceutical company
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Opportunity assessment and market attractiveness for one of the top 10 pharmaceutical major
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Competitor benchmarking and performance gap analysis for a leading European medical device player
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Assessing viability of entering the NSCLC market
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Supplier assessment and industry benchmarking for a global top 10 pharmaceutical company
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Research on a multiple sclerosis drug with help from global neurologists
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach

Procurement in non-Food FMCG Industry
What we are proud of

>50%

savings in staffing costs

25%

increase in outreach